Johnson Controls International plc (NYSE: JCI) saw its shares climb in early trading on Wednesday. First, the company reported fiscal first-quarter 2026 results. These beat consensus estimates. After that, it lifted its full-year outlook. As a result, the stock rose about 8% in pre-market trade.
Quarterly Results in Brief
The company reported Q1 revenue of $5.8 billion. This marked a 7% increase year-over-year. Organic sales grew 6%. GAAP earnings per share hit $0.90. Meanwhile, adjusted EPS reached $0.89. That’s nearly 40% higher than last year. Orders surged 39% organically. Backlog expanded to $18.2 billion, up 20% from a year ago. Net income from continuing operations came in at $555 million. Adjusted net income totaled $547 million.
Margins and Segments Shine
Adjusted margins grew across the board. Americas sales rose 6%. Gross margins there improved roughly 6%. Adjusted segment EBITA margin expanded 20 basis points. EMEA and APAC regions also showed growth. This drove overall margin gains.
Strong Cash and Backlog
Johnson Controls kept solid liquidity. It held about $600 million in cash. Net debt stayed in its target range. Management repeated its goal: about 100% free cash flow conversion for fiscal 2026.
Raised Guidance Looks Bright
The company boosted its full-year 2026 adjusted EPS guidance to $4.70. This signals roughly 25% growth from last year. It still expects mid-single-digit organic revenue growth. For Q2, it forecasts ~5% organic revenue growth. Adjusted EPS should hit around $1.11.
Stock’s 52-Week View
Over the past 52 weeks, JCI shares traded in a wide range. Today’s jump pushed it toward the high end. Investors now show renewed interest. This reflects better execution and demand.
Analyst Notes
No analyst upgrades, downgrades, or price-target changes appeared yet. These would tie directly to today’s earnings.
CEO’s Take
CEO Joakim Weidemanis praised the results. He pointed to strong revenue growth. He also noted margin improvements and a record backlog. These fuel confidence in the company’s strategy.